Abstract:Hypoxia imaging can guide tumor treatment and monitor changes in hypoxia during treatment. However, there is still no ideal hypoxia imaging agent for clinical applications. In this study, two novel 2-nitromidazole derivatives were synthesized and directly radiolabeled by [18F]FDG in high radiochemical yield and excellent radiochemical purity. Cell experiments, biodistribution, and positron emission tomography (PET) imaging studies were also conducted in mice-bearing S180 or OS732 tumors. [18F]FDG-2NNC2ON [(2 R,3 S,4 R, E)-2-18F-fluoro-3,4,5,6-tetrahydroxyhexanal O-3-(2-(2-nitro-1 H-imidazole-1-yl)ethylamino)-2-oxopropyl oxime] and [18F]FDG-2NNC5ON [(2 R,3 S,4 R, E)-2-18F-fluoro-3,4,5,6-tetrahydroxyhexanal-O-3-(5-(2-nitro-1 H-imidazole-1-yl)pentylamino)-2-oxopropyl oxime] can be cleared from the blood quickly and specifically target hypoxic tumor cells. The uptake of the probes by hypoxic cells gradually increases with time. After 4 h, the uptake value of [18F]FDG-2NNC2ON in hypoxic cells is 3.2 times higher than that in normoxia cells. In contrast, there is no difference in the uptake of [18F]FDG between hypoxic cells and normoxia cells. Biodistribution resulting from two tumor models indicate that the uptake values of the two radiotracers in the tumor are higher at 1 h than those at 2 and 4 h. At 1 and 2 h, the tumors are clearly observed on the PET images and the imaging features of [18F]FDG-2NNC5ON and [18F]FDG-2NNC2ON are distinct from those of [18F]FDG. Compared with [18F]FDG-2NNC5ON, [18F]FDG-2NNC2ON has a higher proportion of renal excretion, lower digestive tract uptake, and better imaging contrast because of its higher hydrophilicity. At 2 h, [18F]FDG-2NNC2ON shows a good tumor-to-blood (T/B) ratio, tumor-to-muscle ratio based on biodistribution (Bio-T/M ratio), and tumor-to-muscle ratio based on regions of interest on the PET images [region of interest (ROI)-T/M ratio] in the two tumor models (T/B, Bio-T/M, and ROI-T/M ratios are 3.2, 2.6, and 3.9 in the S180 tumor model and are 3.4, 4.2, and 4.6 in the OS732 tumor model, respectively). The imaging features visualized with autoradiography mostly coincided with the positive areas of HIF1α staining by immunofluorescence. Meanwhile, the biodistribution study and PET imaging revealed that the uptake of the radiotracers in the tumor cannot be competed by 5% glucose, confirming that [18F]FDG-2NNC2ON targets the hypoxic regions of the tumors instead of targeting tumors through the glucose metabolism pathway. These results suggest that the new 2-nitroimidazole derivative conjugated with [18F]FDG, [18F]FDG-2NNC2ON, has potential as an imaging agent for hypoxia.

Preparation and biodistribution of technetium-99m-labeled 1-(2-nitroimidazole-1-yl)-propanhydroxyiminoamide (N2IPA) as a tumor hypoxia marker.

Synthesis and Biological Results of the Technetium-99M-labeled 4-Nitroimidazole for Imaging Tumor Hypoxia

In Vitro and in Vivo Evaluation of A Technetium-99m-Labeled 4-Nitroimidazole As A Tracer for Detection of Tumor Hypoxia

Preparation and Biological Evaluation of 99Mtc-N4ipa for Single Photon Emission Computerized Tomography Imaging of Hypoxia in Mouse Tumor

Preparation and Bioevaluation of a Novel 99Mtc-Labelled Propylene Amine Oxime (pnao) Containing Two 4-Methyl-2-nitroimidazole Groups As a Promising Tumor Hypoxia Imaging Agent

Synthesis And Biodistribution Of Novel Tc-99m Labeled 4-Nitroimidazole Dithiocarbamate Complexes As Potential Agents To Target Tumor Hypoxia

Preparation and Bioevaluation of Novel 99Mtc-Labeled Complexes with a 2-Nitroimidazole HYNIC Derivative for Imaging Tumor Hypoxia

Synthesis and Preliminary Evaluation of a Novel 18F-Labeled 2-Nitroimidazole Derivative for Hypoxia Imaging

Preparation and bioevaluation of a novel 99m Tc-labelled propylene amine oxime (PnAO) containing two 4-methyl-2-nitroimidazole groups as a promising tumor hypoxia imaging agent

Synthesis and Preliminary Evaluation of a Novel <SUP>18</SUP>F-Labeled 2-Nitroimidazole Derivative for Hypoxia Imaging

Preparation and Biological Evaluation of a Technetium-99M Labeled 4-Nitroimidazole Derivative for Imaging Tumor Hypoxia

Novel 99mtc Labelled Complexes with 2-Nitroimidazole Isocyanide: Design, Synthesis and Evaluation As Potential Tumor Hypoxia Imaging Agents.

Biological Evaluation and SPECT Imaging of Tumor Hypoxia Using a Novel Technetium-99M Labeled Tracer with 2-Nitroimidazole Moiety

Improving Tumor/muscle and Tumor/blood Ratios of 99Mtc-Labeled Nitroimidazole Propylene Amine Oxime (pnao) Complexes with Ethylene Glycol Linkers.

[Tc-99M(co)(3)](+) Labeled Histidine Derivative Containing 4-Nitroimidazole: Synthesis, Biodistribution As A Tumor Hypoxia Imaging Agent

Development of (99m)Tc-N4-NIM for molecular imaging of tumor hypoxia

Preparation and biological evaluation of two novel 99mTc-nitrido complexes of metronidazole derivative for targeting hypoxia

Synthesis and Biodistribution of the 99m Tc Nitrido Complex with 2-(4-nitro-1h-imidazolyl)ethyl Dithiocarbamate (NIET)

Synthesis and evaluation of [99mTcN]2+ core and [99mTcO]3+ core labeled complexes with 4-nitroimidazole xanthate derivative for tumor hypoxia imaging

Preparation and Biological Evaluation of Two Novel Tc-99m-nitrido Complexes of Metronidazole Derivative for Targeting Hypoxia

Synthesis and Bioevaluation of Novel [18F]fdg-Conjugated 2-Nitroimidazole Derivatives for Tumor Hypoxia Imaging.